Post-Bristol/Myers buyout, the IFM team lines up $31M to tackle a troika of NLRP3 targets
After years of lab work, the NLRP3 inflammasome has emerged as a prominent drug target in the biopharma world.
Just weeks after the UK’s …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
